XML 64 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License and Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended 41 Months Ended
Nov. 30, 2020
USD ($)
Jan. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Apr. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2022
USD ($)
Aug. 31, 2021
USD ($)
Jun. 30, 2021
Program
Mar. 31, 2024
USD ($)
License
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
License
Jul. 31, 2021
USD ($)
Jan. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Development cost reimbursement received   $ 15,000,000                            
Revenue                   $ 172,325,000 $ 44,846,000          
Accrued expenses                   101,399,000   $ 127,806,000 $ 101,399,000      
EMPAVELI [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Revenue                   25,610,000 20,440,000          
SYFOVRE [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Revenue                   137,465,000 18,360,000          
Regulatory milestone payments   3,000,000 $ 2,000,000 $ 2,300,000                        
Regulatory milestone incurred                       5,000,000        
Royalty expense incurred                   13,400,000     13,400,000      
Empaveli And Aspaveli [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone payments based on annual sales milestones   1,500,000                            
Royalty expense incurred                   9,500,000     9,500,000      
Swedish Orphan Biovitrum AB (Publ) [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Royalty revenue                   4,500,000 1,600,000          
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront payment $ 250,000,000                              
Milestone payment received for achievement of regulatory development milestone             $ 50,000,000                  
Development cost reimbursement                   80,000,000            
Development cost reimbursement received                   65,000,000            
Waived Payment                   $ 15,000,000            
Royalties entitled to receive after first commercial sale of applicable licensed product period                   10 years            
Contract research and development expense                   $ 0 $ 0   65,000,000      
Contract research and development current                       $ 15,000,000        
Remaining reimbursement payment   15,000,000                            
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events                               $ 915,000,000
University of Pennsylvania [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Development milestone achievement           $ 5,000,000   $ 1,000,000                
University of Pennsylvania [Member] | Empaveli And Aspaveli [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone payments based on annual sales milestones         $ 1,000,000                      
University of Pennsylvania [Member] | Maximum [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Aggregate milestones payments                   3,200,000     $ 3,200,000      
Milestone payments based on annual sales milestones                   $ 5,000,000            
2010 License Agreement [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Number of licensed products | License                   2     2      
2010 License Agreement [Member] | Maximum [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Aggregate milestones payments                   $ 1,700,000     $ 1,700,000      
Milestone payments based on annual sales milestones                   $ 2,500,000            
Sobi Agreement and Another Licensing Transaction [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Sublicense fee owed   $ 500,000                         $ 25,000,000  
Research Collaboration Agreement [Member] | Beam [Member]                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Collaboration agreement term                 5 years              
Number of research programs | Program                 6              
Up-front non-refundable payment                           $ 50,000,000    
Up-front payment on first anniversary of agreement on June 30, 2022           $ 25,000,000                    
Collaboration agreement maximum extendable term           2 years